Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| InspireMD, Inc.NSPR · Entity 7318 | Chief Commercial Officer | January 27, 2025 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
InspireMD, Inc.
Report date January 27, 2025 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,053,882 |
Ending reported balance
After 2026-05-19 transaction · row 14
14 source rows · reconciled sequenceRow 1 · 2025-01-27 · Sale · Disposed 3,858 · Balance 1,135,319 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 2 · 2025-01-28 · Sale · Disposed 2,476 · Balance 1,132,843 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 3 · 2025-01-29 · Sale · Disposed 3,660 · Balance 1,129,183 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 4 · 2025-01-30 · Sale · Disposed 2,454 · Balance 1,126,729 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 5 · 2025-01-31 · Sale · Disposed 9,923 · Balance 1,116,806 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 6 · 2025-02-03 · Sale · Disposed 7,073 · Balance 1,109,733 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 7 · 2025-02-04 · Sale · Disposed 5,132 · Balance 1,104,601 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 8 · 2025-02-25 · Sale · Disposed 10,000 · Balance 1,094,601 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 9 · 2025-05-23 · Sale · Disposed 2,482 · Balance 1,092,119 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 10 · 2025-05-27 · Sale · Disposed 1,572 · Balance 1,090,547 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 11 · 2025-05-29 · Sale · Disposed 3,760 · Balance 1,086,787 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 12 · 2025-05-30 · Sale · Disposed 7,186 · Balance 1,079,601 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 13 · 2026-02-02 · Sale · Disposed 2,941 · Balance 1,076,660 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Row 14 · 2026-05-19 · Sale · Disposed 22,778 · Balance 1,053,882 F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. F2: The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.00 to $1.04. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person.
F2: The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.00 to $1.04. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 22,778 | $1.01 | $23,005.78 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 14 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,053,882 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. F2 · price: The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.00 to $1.04. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| February 02, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,000 | $1.60 | $3,208.00 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 10 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,139,177 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 02, 2026 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,941 | $1.59 | $4,676.19 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 13 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,660 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,900 | $1.63 | $4,729.90 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 9 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,141,177 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 5,000 | $1.65 | $8,250.00 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 8 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,077 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 28, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 12,395 | $1.65 | $20,464.15 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 7 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,149,077 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 27, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 4,781 | $1.66 | $7,955.58 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 6 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,472 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 22, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 8,411 | $1.57 | $13,238.91 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 5 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,166,253 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 21, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 17,593 | $1.62 | $28,553.44 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 4 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,174,664 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 20, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,955 | $1.59 | $4,710.27 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 3 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,192,257 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 16, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,250 | $1.61 | $3,627.00 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 2 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,195,212 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 15, 2026 Filed Feb 2, 2026 22:01 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,909 | $1.58 | $4,593.31 |
DisclosureSEC source: 0001493152-26-004773 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,197,462 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 23:09 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 453,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002665 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,371 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to the Reporting Person's continued service. Read SEC document |
| May 30, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 7,186 | $2.51 | $18,036.86 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 12 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,079,601 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| May 29, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 3,760 | $2.51 | $9,437.60 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 11 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,086,787 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| May 27, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 1,572 | $2.51 | $3,945.72 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 10 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,090,547 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| May 23, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,482 | $2.51 | $6,229.82 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 9 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,092,119 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| February 25, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 10,000 | $3.65 | $36,500.00 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 8 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,094,601 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| February 04, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 5,132 | $2.46 | $12,624.72 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 7 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,104,601 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| February 03, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 7,073 | $2.51 | $17,753.23 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 6 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,109,733 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 31, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 9,923 | $2.55 | $25,303.65 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 5 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,116,806 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 30, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,454 | $2.51 | $6,159.54 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 4 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,126,729 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 29, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 3,660 | $2.46 | $9,003.60 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 3 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,183 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 28, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 2,476 | $2.61 | $6,462.36 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 2 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,132,843 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 27, 2025 Filed May 21, 2026 21:16 UTC | InspireMD, Inc. NSPR · Entity 7318 | SaleCommon Stock | 3,858 | $2.71 | $10,455.18 |
DisclosureSEC source: 0001493152-26-024864 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,135,319 F1 · shares: The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 106,218 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001493152-25-001727 · ownership.xml · derivative · entry 2 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,346 Underlying: Common Stock · 106,218 shares Expires 2035-01-07 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of January 7, 2026, January 7, 2027 and January 7, 2028, subject to the Reporting Person's continued service. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:30 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 232,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-001727 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,981 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 7, 2026, January 7, 2027 and January 7, 2028, subject to the Reporting Person's continued service. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:52 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 91,218 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001493152-24-003777 · ownership.xml · derivative · entry 2 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,128 Underlying: Common Stock · 91,218 shares Expires 2034-01-23 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of January 23, 2025, January 23, 2026 and January 23, 2027, subject to the Reporting Person's continued service. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:52 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 238,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-003777 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,365 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 23, 2025, January 23, 2026 and January 23, 2027, subject to the Reporting Person's continued service. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:15 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 6,430 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001493152-23-030663 · ownership.xml · derivative · entry 2 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,910 Underlying: Common Stock · 6,430 shares Expires 2033-08-28 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of August 28, 2024, August 28, 2025 and August 28, 2026, subject to the Reporting Person's continued service. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:15 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 19,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-030663 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,740 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of August 28, 2024, August 28, 2025 and August 28, 2026, subject to the Reporting Person's continued service. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:15 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantOptions to purchase common stock (right to buy) · Derivative | 85,480 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001493152-23-018337 · ownership.xml · derivative · entry 2 Gleason Shane Thomas · CIK 0001966214 · VP Global Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,480 Underlying: Common Stock · 85,480 shares Expires 2033-05-17 F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:15 UTC | InspireMD, Inc. NSPR · Entity 7318 | GrantCommon Stock | 256,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-018337 · ownership.xml · nonDerivative · entry 1 Gleason Shane Thomas · CIK 0001966214 · VP Global Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,450 F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.